Defining the differences between episodic migraine and chronic migraine

Zaza Katsarava, Dawn C Buse, Aubrey N Manack, Richard B Lipton, Zaza Katsarava, Dawn C Buse, Aubrey N Manack, Richard B Lipton

Abstract

Chronic migraine (CM) and episodic migraine (EM) are part of the spectrum of migraine disorders, but they are distinct clinical entities. Population-based studies have shown that those with CM demonstrate higher individual and societal burden because they are significantly more disabled than those with EM and have greater impaired quality of life both inside and outside the home. Proper diagnosis of both conditions requires clearly defined clinical criteria. Diagnosis enables the initiation of appropriate treatments and risk-factor modification, which ultimately improve functional status and quality of life for persons with migraine. Recognizing that both disorders are on the spectrum of migraine, this review serves as a guide to define the disease state of CM as distinct from EM in terms of clinical, epidemiological, sociodemographic, and comorbidity profiles.

References

    1. World Health Organization. Headache disorders. Fact sheet N°277. . 2004.
    1. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210. doi: 10.1111/j.1468-2982.2007.01288.x.
    1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004, 24 Suppl 1:9–160.
    1. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, Gobel H, Lainez MJ, Lance JW, Lipton RB, Nappi G, Sakai F, Schoenen J, Silberstein SD, Steiner TJ. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–746. doi: 10.1111/j.1468-2982.2006.01172.x.
    1. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008;48:1157–1168. doi: 10.1111/j.1526-4610.2008.01217.x.
    1. Manack A, Buse DC, Serrano D, Turkel CC, Lipton RB. Rates, predictors, and consequences of remission from chronic migraine to episodic migraine. Neurology. 2011;76:711–718. doi: 10.1212/WNL.0b013e31820d8af2.
    1. •• Blumenfeld A, Varon S, Wilcox TK, Buse D, Kawata AK, Manack A, Goadsby PJ, Lipton RB: Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia 2011, 31:301–315. This is the only international (nine countries) study of migraine epidemiology. A web-based survey was used to compare those with episodic migraine to those with chronic migraine on headache features, headache-related disability, health-related quality of life, health care resource utilization, and medical and psychiatric comorbidities.
    1. •• Buse DC, Manack A, Serrano D, Turkel C, Lipton RB: Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 2010, 81:428–432.This population-based study from the United States demonstrates that those with chronic migraine were significantly more likely to have a lower socioeconomic status and more psychiatric/medical comorbidities than those with episodic migraine.
    1. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–566. doi: 10.1212/01.wnl.0000323925.29520.e7.
    1. •• Katsarava Z, Manack A, Yoon M-S, Obermann M, Becker H, Dommes P, Turkel C, Lipton RB, Diener HC: Chronic migraine: Classification and comparisons. Cephalalgia 2011, published on January 10, 2011 as doi:10.1177/0333102410383590. This epidemiologic study of a random population in Germany used three different definitions of chronic migraine and demonstrated that the epidemiological profiles of the three groups were similar but differ significantly from those with high- or low-frequency episodic migraine. The prevalence of chronic migraine also differed depending on the definition used.
    1. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–349. doi: 10.1212/01.wnl.0000252808.97649.21.
    1. Reed ML, Buse DC, Manack AN, Fanning KM, Serrano D, Turkel CC, Lipton RB: Prevalence of chronic migraine (CM), headache-related disability and sociodemographic factors in the US population: Results from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2011, 51:28 [abstract P58].
    1. • Natoli J, Manack A, Dean B, Butler Q, Turkel C, Stovner L, Lipton R: Global prevalence of chronic migraine: a systematic review. Cephalalgia 2010, 30:599–609. This review article describes the population prevalence of chronic migraine across different populations and explores the various diagnostic criteria for chronic migraine.
    1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 8 Suppl 7:1–96.
    1. Silberstein SD, Lipton RB, Solomon S, Mathew N: Classification of daily and near-daily headaches in the headache clinic. Proposed revisions to the International Headache Society criteria. In Frontiers in Headache Research. Edited by Olesen J. New York: Raven Press, Ltd; 1994:117–126.
    1. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996;47:871–875.
    1. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology. 2008;70:1525–1533. doi: 10.1212/01.wnl.0000310645.31020.b1.
    1. Dodick DW, Turkel CC, DeGryse R, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. on behalf of the PREEMPT Chronic Migraine Study Group: OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–936. doi: 10.1111/j.1526-4610.2010.01678.x.
    1. Buse DC, Manack AN, Serrano D, Varon SF, Turkel CC, Lipton RB: Headache impact of chronic and episodic migraine: Predictors of impact from the American Migraine Prevalence and Prevention (AMPP) study. Headache 2011, in press.
    1. Stewart WF, Wood GC, Manack A, Varon SF, Buse DC, Lipton RB. Employment and Work Impact of Chronic Migraine and Episodic Migraine. J Occup. Environ. Med. 2010;52:8–14. doi: 10.1097/JOM.0b013e3181c1dc56.
    1. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, Reed M, Lipton RB. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. Headache. 2009;49:498–508. doi: 10.1111/j.1526-4610.2009.01369.x.
    1. Stokes M, Becker WJ, Lipton RB, Sullivan SD, Wilcox TK, Wells L, Manack A, Proskorovsky I, Gladstone J, Buse DC, Varon SF, Goadsby PJ, Blumenfeld AM. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International Burden of Migraine Study (IBMS) Headache. 2011;51:1058–1077. doi: 10.1111/j.1526-4610.2011.01945.x.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen. Intern. Med. 2001;16:606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7–15. doi: 10.1111/j.1526-4610.2007.00969.x.
    1. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;46:1334–1343. doi: 10.1111/j.1526-4610.2006.00577.x.
    1. Lipton RB. Tracing transformation: chronic migraine classification, progression, and epidemiology. Neurology. 2009;72:S3–S7. doi: 10.1212/WNL.0b013e3181974b19.
    1. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology. 2006;67:252–257. doi: 10.1212/01.wnl.0000225052.35019.f9.
    1. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60:1308–1312.
    1. Ashina S, Serrano D, Lipton RB, Maizels M, Manack AN, Turkel CC, Reed ML, Buse DC: Depression is a risk factor for the transformation of episodic to chronic migraine. Cephalalgia 2011, under review.
    1. Vargas BB, Dodick DW. The face of chronic migraine: epidemiology, demographics, and treatment strategies. Neurol Clin. 2009;27:467–479. doi: 10.1016/j.ncl.2009.01.001.
    1. Tietjen GE, Peterlin BL, Brandes JL, Hafeez F, Hutchinson S, Martin VT, Dafer RM, Aurora SK, Stein MR, Herial NA, Utley C, White L, Khuder SA. Depression and anxiety: effect on the migraine-obesity relationship. Headache. 2007;47:866–875. doi: 10.1111/j.1526-4610.2007.00810.x.
    1. Scher AI, Stewart WF, Buse D, Krantz DS, Lipton RB. Major life changes before and after the onset of chronic daily headache: a population-based study. Cephalalgia. 2008;28:868–876. doi: 10.1111/j.1468-2982.2008.01634.x.
    1. Diener HC, Limmroth V. Medication-overuse headache: a worldwide problem. Lancet Neurol. 2004;3:475–483. doi: 10.1016/S1474-4422(04)00824-5.
    1. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, Diener HC, Limmroth V. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788–790.
    1. Zwart JA, Dyb G, Hagen K, Svebak S, Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology. 2003;61:160–164.
    1. Wang SJ, Fuh JL, Lu SR, Liu CY, Hsu LC, Wang PN, Liu HC. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54:314–319.
    1. Lu SR, Fuh JL, Chen WT, Juang KD, Wang SJ. Chronic daily headache in Taipei, Taiwan: prevalence, follow-up and outcome predictors. Cephalalgia. 2001;21:980–986. doi: 10.1046/j.1468-2982.2001.00294.x.
    1. Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: a population-based study. Neurology. 2004;63:2022–2027.
    1. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9:285–298. doi: 10.1016/S1474-4422(10)70005-3.
    1. • Lipton RB, Chu MK: Conceptualizing the relationship between chronic migraine and episodic migraine. Expert Rev Neurother. 2009, 9:1451–1454. This is the first editorial to describe that chronic migraine and episodic migraine are distinct but intimately related disorders.
    1. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–823. doi: 10.1111/j.1468-2982.2007.01326.x.
    1. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007;47:170–180. doi: 10.1111/j.1526-4610.2006.00684.x.
    1. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–1714. doi: 10.1212/01.wnl.0000311390.87642.d8.
    1. Aurora SK, Dodick DW, Turkel CC, DeGryse R, Silberstein SD, Lipton RB, Diener HC, Brin MF, on behalf of PREEMPT 1 Chronic Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30:793–803. doi: 10.1177/0333102410364676.
    1. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse R, Lipton RB, Silberstein SD, Brin MF, on behalf of the PREEMPT 2 Chronic Migraine Study Group OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–814. doi: 10.1177/0333102410364677.
    1. Diener HC, Holle D, Dodick D. Treatment of chronic migraine. Curr Pain Headache Rep. 2010;15:64–69. doi: 10.1007/s11916-010-0159-x.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi